EAACI Biologicals Guidelines - Recommendations for severe asthma
Loading...
Files
Accepted Version
Supplementary Material
Date
2020-06-02
Authors
Agache, Ioana
Akdis, Cezmi A.
Akdis, Mubeccel
Canonica, Giorgio Walter
Casale, Thomas
Chivato, Tomas
Corren, Jonathan
Chu, Derek K.
Del Giacco, Stefano
Eiwegger, Thomas
Journal Title
Journal ISSN
Volume Title
Publisher
John Wiley & Sons, Inc.
Published Version
Abstract
Severe asthma imposes a significant burden on patients, families and healthcare systems. Management is difficult, due to disease heterogeneity, co-morbidities, complexity in care pathways and differences between national or regional healthcare systems. Better understanding of the mechanisms has enabled a stratified approach to the management of severe asthma, supporting the use of targeted treatments with biologicals. However, there are still many issues that require further clarification. These include selection of a certain biological (as they all target overlapping disease phenotypes), the definition of response, strategies to enhance the responder rate, the duration of treatment and its regimen (in the clinic or home-based) and its cost-effectiveness. The EAACI Guidelines on the use of biologicals in severe asthma follow the GRADE approach in formulating recommendations for each biological and each outcome. In addition, a management algorithm for the use of biologicals in the clinic is proposed, together with future approaches and research priorities.
Description
Keywords
Biologicals , Cost-effectiveness , GRADE , Guidelines , Severe asthma
Citation
Agache, I., Akdis, C. A., Akdis, M., Canonica, G. W., Casale, T., Chivato, T., Corren, J., Chu, D. K., Del Giacco, S., Eiwegger, T., Flood, B., Firinu, D., Gern, J. E., Hamelmann, E., Hanania, N., Hernández-Martín, I., Knibb, R., Mäkelä, M., Nair, P., O'Mahony, L., Papadopoulos, N. G., Papi, A., Park, H.-S., Pérez de Llano, L., Pfaar, O., Quirce, S., Sastre, J., Shamji, M., Schwarze, J., Palomares, O. and Jutel, M. (2020) 'EAACI Biologicals Guidelines - Recommendations for severe asthma', Allergy, 76(1), pp. 14-44. doi: 10.1111/all.14425
Link to publisher’s version
Collections
Copyright
© 2020, EAACI and John Wiley and Sons A/S. Published by John Wiley and Sons Ltd. This is the peer reviewed version of the following article: Agache, I., Akdis, C. A., Akdis, M., Canonica, G. W., Casale, T., Chivato, T., Corren, J., Chu, D. K., Del Giacco, S., Eiwegger, T., Flood, B., Firinu, D., Gern, J. E., Hamelmann, E., Hanania, N., Hernández-Martín, I., Knibb, R., Mäkelä, M., Nair, P., O'Mahony, L., Papadopoulos, N. G., Papi, A., Park, H.-S., Pérez de Llano, L., Pfaar, O., Quirce, S., Sastre, J., Shamji, M., Schwarze, J., Palomares, O. and Jutel, M. (2020) 'EAACI Biologicals Guidelines - Recommendations for severe asthma', Allergy, 76(1), pp. 14-44, doi: 10.1111/all.14425, which has been published in final form at: https://doi.org/10.1111/all.14425 This article may be used for non-commercial purposes in accordance with Wiley Terms and Conditions for Use of Self-Archived Versions.